Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Increases in postprandial apoCIII after fructose, but not glucose consumption, are positively associated with elevated triglycerides in large triglyceride-rich lipoproteins and increased small dense LDL levels.
|
31789670 |
2020 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Therefore, there appears to be a need for effective TG-lowering agents.<b>Areas covered</b>: This review presents the most recent advances in hypertriglyceridemia treatment; specifically, it discusses the results of clinical trials and critically comments on apolipoprotein C-III inhibitors, angiopoietin-like 3 inhibitors, alipogene tiparvovec, pradigastat, pemafibrate and novel formulations of omega-3 fatty acids.<b>Expert opinion</b>: In the era of extreme lowering of LDL-C levels with several agents, there seems to be space for novel therapeutic options to combat parameters responsible for residual CVD risk, among which are elevated TGs.
|
31738617 |
2020 |
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Elevated apolipoprotein C-III (apoC-III) levels are associated with hypertriglyceridaemia and coronary heart disease.
|
31329855 |
2019 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To investigate whether hypertriglyceridemia subtypes affect acute pancreatitis progression, we analyzed two genetically modified hypertriglyceridemia mouse models-namely, glycosylphosphatidylinositol high-density lipoprotein binding protein 1 knockout (Gpihbp1-/-) and apolipoprotein C3 transgenic (ApoC3-tg) mice.
|
31570698 |
2019 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, RNAi-mediated ApoC3 inhibition lowered plasma TG concentrations in animals with diet-induced hypertriglyceridemia.
|
30723097 |
2019 |
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The underlying mechanism may be improved glycaemic control, which leads to reduced expression of apoCIII, a key regulator of hypertriglyceridaemia in hyperglycaemic patients.
|
30073766 |
2019 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Apolipoprotein C3 (apoC3) is associated with hypertriglyceridemia and is therefore closely related to CHD.
|
30511426 |
2019 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
RRFs were obtained by ethanol extraction from Rosa rugosa Thunb.. Transgenic mice expressing human Apolipoprotein C3 (ApoC3) were used as a mouse model of hypertriglyceridemia.
|
31100436 |
2019 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To analyze the association between genetic polymorphisms of apolipoprotein genes APOA5, APOC3, and APOE and the severity of hypertriglyceridemia during bexarotene therapy and to optimize patient selection for bexarotene therapy based on adverse effect profile.
|
30422238 |
2018 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
apoB = apolipoprotein B; apoC-III = apolipoprotein CIII; ASO = antisense oligonucleotide; FCS = familial chylomicronemia syndrome; HTG = hypertriglyceridemia; LPL = lipoprotein lipase; LPLD = lipoprotein lipase deficiency.
|
30183397 |
2018 |
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The apoC-III Gln38Lys variant was identified in subjects of Mexican origin with moderate hypertriglyceridemia.
|
28887372 |
2017 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results indicate that apoCIII and/or hypertriglyceridemia plays a major role in liver inflammation and cell death, which in turn increases susceptibility to and the severity of diet-induced NAFLD.
|
28163820 |
2017 |
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Particularly, the variants rs632153, rs633389, rs2187126 and rs1263163 might be risk conferring to dyslipidemia by elevating LDLC and TC levels, while the variants of APOC3 and APOA1 genes might be the genetic determinants of elevated triglycerides in the present population.
|
28610615 |
2017 |
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Humans with APOC3 gain-of-function mutations and mice with APOC3 overproduction are associated with hypertriglyceridemia.
|
28115523 |
2017 |
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
PCSK9 significantly conferred prediction of both hypercholesterolemia and combined hyperlipidemia at a level of 235 ng/ml; apoC3 levels for hypertriglyceridemia, hypercholesterolemia and combined hyperlipidemia were 80.0, 71.5, and 86.4 μg/ml, respectively; and sdLDL-C for hypertriglyceridemia, hypercholesterolemia, combined hyperlipidemia and hypo high density lipoprotein (HDL) cholesterolemia 3.5, 2.5, 4.5, and 2.5 mg/dl, respectively (all p<0.001 for area under the receiver-operating characteristic curve).
|
27713142 |
2017 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The agent blocks the function of the mRNA of apolipoprotein C3 and successfully treats severe hypertriglyceridaemia in phase 3 trials (Ionis Pharmaceuticals).
|
28441154 |
2017 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Apolipoprotein C-III has been referred to as an important participant in the metabolism of triglyceride-rich lipoproteins, leading to hypertriglyceridemia and thereafter cardiovascular disease.
|
27770802 |
2016 |
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We assessed the effects on these complexes of placebo or 100-300 mg volanesorsen, a generation 2.0+ antisense drug that targets apoC3 mRNA in patients with hypertriglyceridemia, including familial chylomicronemia syndrome (n = 3), volanesorsen monotherapy (n = 51), and as add-on to fibrate (n = 26), treated for 85 days and followed for 176 days.
|
26848137 |
2016 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We showed that ApoC3-transgenic mice, as opposed to age/sex-matched wild-type littermates, develop hypertriglyceridemia with concomitant elevations in plasma cholesterol and non-esterified fatty acid levels.
|
27226540 |
2016 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We sequenced APOC3 3'UTR in 100 type 2 diabetic (TD2) patients with severe HTG (TG > 15 mmol/L) (HTG group) compared to 100 normotriglyceridemic patients (NTG group).
|
27794214 |
2016 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We first used the human Apolipoprotein CIII transgenic (Tg-ApoCIII) mice and non-transgenic (Non-Tg) littermates to examine the effect of HTG on stroke.
|
26970521 |
2016 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here, we review the pathophysiological role of apoC-III in TG metabolism and the evidence supporting this apolipoprotein as an emerging target for hypertriglyceridemia (HTG) and associated cardiovascular disorders.
|
26435212 |
2015 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results indicate that the metabolic response to HTG in human apolipoprotein C-III overexpressing mice may support a high TG production rate and that the cytosol of hepatocytes is subjected to an important oxidative stress, probably as a result of FFA over-accumulation, iron overload and enhanced activity of some ROS-producing catabolic enzymes.
|
25047818 |
2014 |
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Likelihood ratio test showed a strong interaction for increasing risk of early IHD between the presence of ApoC3 and 9p21.3 locus with hypertriglyceridemia (p=0.0008, 0.0011) as well as between 9p21.3 locus and smoking (p=0.0010) after correction for multiple testing.
|
24656450 |
2014 |
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Several therapies for regulating TRL metabolism, including inhibitors of diacylglycerol O-acyltransferase and microsomal triglyceride transfer protein, and apoC-III antisense oligonucleotides, merit further investigation in patients with hypertriglyceridaemia.
|
24060958 |
2013 |